Tumor Necrosis Factor Receptor Superfamily Member 10A (Death Receptor 4 or TNF Related Apoptosis Inducing Ligand Receptor 1 or TRAIL Receptor 1 or DR4 or CD261 or TNFRSF10A) - Pipeline Review, H2 2017
Tumor Necrosis Factor Receptor Superfamily Member 10A (Death Receptor 4 or TNF Related Apoptosis Inducing Ligand Receptor 1 or TRAIL Receptor 1 or DR4 or CD261 or TNFRSF10A) - Pipeline Review, H2 2017
SUMMARY
Tumor Necrosis Factor Receptor Superfamily Member 10A (Death Receptor 4 or TNF Related Apoptosis Inducing Ligand Receptor 1 or TRAIL Receptor 1 or DR4 or CD261 or TNFRSF10A) pipeline Target constitutes close to 16 molecules. Out of which approximately 12 molecules are developed by companies and remaining by the universities/institutes. The latest report Tumor Necrosis Factor Receptor Superfamily Member 10A - Pipeline Review, H2 2017, outlays comprehensive information on the Tumor Necrosis Factor Receptor Superfamily Member 10A (Death Receptor 4 or TNF Related Apoptosis Inducing Ligand Receptor 1 or TRAIL Receptor 1 or DR4 or CD261 or TNFRSF10A) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
Tumor Necrosis Factor Receptor Superfamily Member 10A (Death Receptor 4 or TNF Related Apoptosis Inducing Ligand Receptor 1 or TRAIL Receptor 1 or DR4 or CD261 or TNFRSF10A) - Tumor necrosis factor receptor superfamily member 10A (TNFRSF10A) or Death receptor 4 (DR4) is a protein encoded by TNFRSF10A. This receptor is activated by tumor necrosis factor-related apoptosis inducing ligand (TNFSF10/TRAIL), and thus transduces cell death signal and induces cell apoptosis. It promotes the activation of NF-kappa-B. The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 1, 1, 7 and 1 respectively. Similarly, the universities portfolio in Preclinical stages comprises 4 molecules, respectively. Report covers products from therapy areas Oncology, Central Nervous System, Hematological Disorders and Immunology which include indications Colon Cancer, Colorectal Cancer, Hepatocellular Carcinoma, Solid Tumor, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Burkitt Lymphoma, Head And Neck Cancer, Malignant Ascites, Multiple Myeloma (Kahler Disease), Multiple Sclerosis, Non-Hodgkin Lymphoma, Non-Small Cell Lung Cancer, Non-Small Cell Lung Carcinoma, Refractory Multiple Myeloma, Relapsed Multiple Myeloma, Renal Cell Carcinoma and Rheumatoid Arthritis.
Furthermore, this report also reviews key players involved in Tumor Necrosis Factor Receptor Superfamily Member 10A (Death Receptor 4 or TNF Related Apoptosis Inducing Ligand Receptor 1 or TRAIL Receptor 1 or DR4 or CD261 or TNFRSF10A) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
SUMMARY
Tumor Necrosis Factor Receptor Superfamily Member 10A (Death Receptor 4 or TNF Related Apoptosis Inducing Ligand Receptor 1 or TRAIL Receptor 1 or DR4 or CD261 or TNFRSF10A) pipeline Target constitutes close to 16 molecules. Out of which approximately 12 molecules are developed by companies and remaining by the universities/institutes. The latest report Tumor Necrosis Factor Receptor Superfamily Member 10A - Pipeline Review, H2 2017, outlays comprehensive information on the Tumor Necrosis Factor Receptor Superfamily Member 10A (Death Receptor 4 or TNF Related Apoptosis Inducing Ligand Receptor 1 or TRAIL Receptor 1 or DR4 or CD261 or TNFRSF10A) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
Tumor Necrosis Factor Receptor Superfamily Member 10A (Death Receptor 4 or TNF Related Apoptosis Inducing Ligand Receptor 1 or TRAIL Receptor 1 or DR4 or CD261 or TNFRSF10A) - Tumor necrosis factor receptor superfamily member 10A (TNFRSF10A) or Death receptor 4 (DR4) is a protein encoded by TNFRSF10A. This receptor is activated by tumor necrosis factor-related apoptosis inducing ligand (TNFSF10/TRAIL), and thus transduces cell death signal and induces cell apoptosis. It promotes the activation of NF-kappa-B. The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 1, 1, 7 and 1 respectively. Similarly, the universities portfolio in Preclinical stages comprises 4 molecules, respectively. Report covers products from therapy areas Oncology, Central Nervous System, Hematological Disorders and Immunology which include indications Colon Cancer, Colorectal Cancer, Hepatocellular Carcinoma, Solid Tumor, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Burkitt Lymphoma, Head And Neck Cancer, Malignant Ascites, Multiple Myeloma (Kahler Disease), Multiple Sclerosis, Non-Hodgkin Lymphoma, Non-Small Cell Lung Cancer, Non-Small Cell Lung Carcinoma, Refractory Multiple Myeloma, Relapsed Multiple Myeloma, Renal Cell Carcinoma and Rheumatoid Arthritis.
Furthermore, this report also reviews key players involved in Tumor Necrosis Factor Receptor Superfamily Member 10A (Death Receptor 4 or TNF Related Apoptosis Inducing Ligand Receptor 1 or TRAIL Receptor 1 or DR4 or CD261 or TNFRSF10A) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
- The report provides a snapshot of the global therapeutic landscape for Tumor Necrosis Factor Receptor Superfamily Member 10A (Death Receptor 4 or TNF Related Apoptosis Inducing Ligand Receptor 1 or TRAIL Receptor 1 or DR4 or CD261 or TNFRSF10A)
- The report reviews Tumor Necrosis Factor Receptor Superfamily Member 10A (Death Receptor 4 or TNF Related Apoptosis Inducing Ligand Receptor 1 or TRAIL Receptor 1 or DR4 or CD261 or TNFRSF10A) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Tumor Necrosis Factor Receptor Superfamily Member 10A (Death Receptor 4 or TNF Related Apoptosis Inducing Ligand Receptor 1 or TRAIL Receptor 1 or DR4 or CD261 or TNFRSF10A) targeted therapeutics and enlists all their major and minor projects
- The report assesses Tumor Necrosis Factor Receptor Superfamily Member 10A (Death Receptor 4 or TNF Related Apoptosis Inducing Ligand Receptor 1 or TRAIL Receptor 1 or DR4 or CD261 or TNFRSF10A) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Tumor Necrosis Factor Receptor Superfamily Member 10A (Death Receptor 4 or TNF Related Apoptosis Inducing Ligand Receptor 1 or TRAIL Receptor 1 or DR4 or CD261 or TNFRSF10A) targeted therapeutics
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Tumor Necrosis Factor Receptor Superfamily Member 10A (Death Receptor 4 or TNF Related Apoptosis Inducing Ligand Receptor 1 or TRAIL Receptor 1 or DR4 or CD261 or TNFRSF10A)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Tumor Necrosis Factor Receptor Superfamily Member 10A (Death Receptor 4 or TNF Related Apoptosis Inducing Ligand Receptor 1 or TRAIL Receptor 1 or DR4 or CD261 or TNFRSF10A) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Introduction
Global Markets Direct Report Coverage
Tumor Necrosis Factor Receptor Superfamily Member 10A (Death Receptor 4 or TNF Related Apoptosis Inducing Ligand Receptor 1 or TRAIL Receptor 1 or DR4 or CD261 or TNFRSF10A) - Overview
Tumor Necrosis Factor Receptor Superfamily Member 10A (Death Receptor 4 or TNF Related Apoptosis Inducing Ligand Receptor 1 or TRAIL Receptor 1 or DR4 or CD261 or TNFRSF10A) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Tumor Necrosis Factor Receptor Superfamily Member 10A (Death Receptor 4 or TNF Related Apoptosis Inducing Ligand Receptor 1 or TRAIL Receptor 1 or DR4 or CD261 or TNFRSF10A) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Tumor Necrosis Factor Receptor Superfamily Member 10A (Death Receptor 4 or TNF Related Apoptosis Inducing Ligand Receptor 1 or TRAIL Receptor 1 or DR4 or CD261 or TNFRSF10A) - Companies Involved in Therapeutics Development
AbbVie Inc
Galaxy Biotech LLC
GlaxoSmithKline Plc
KAHR medical Ltd
Merrimack Pharmaceuticals Inc
Tumor Necrosis Factor Receptor Superfamily Member 10A (Death Receptor 4 or TNF Related Apoptosis Inducing Ligand Receptor 1 or TRAIL Receptor 1 or DR4 or CD261 or TNFRSF10A) - Drug Profiles
ABBV-621 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AY-4 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Biologic to Agonize TRAIL Receptor 1 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CD19L-sTRAIL - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
dulanermin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Fusion Protein to Agonize DR4 and DR5 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HuD-114 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HuYON-007 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KAHR-101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
M-921 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
mapatumumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Recombinant Protein for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Recombinant Protein to Agonize TNFRSF10A, TNFRSF10B, TNFRSF10C and TNFRSF10D for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SCB-313 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SL-231 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Agonize DR4 and DR5 for Colorectal Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Tumor Necrosis Factor Receptor Superfamily Member 10A (Death Receptor 4 or TNF Related Apoptosis Inducing Ligand Receptor 1 or TRAIL Receptor 1 or DR4 or CD261 or TNFRSF10A) - Dormant Products
Tumor Necrosis Factor Receptor Superfamily Member 10A (Death Receptor 4 or TNF Related Apoptosis Inducing Ligand Receptor 1 or TRAIL Receptor 1 or DR4 or CD261 or TNFRSF10A) - Discontinued Products
Tumor Necrosis Factor Receptor Superfamily Member 10A (Death Receptor 4 or TNF Related Apoptosis Inducing Ligand Receptor 1 or TRAIL Receptor 1 or DR4 or CD261 or TNFRSF10A) - Product Development Milestones
Featured News & Press Releases
Nov 21, 2017: AbbVie to Present Data on Cancer Drug Candidate ABBV-621 at the 2017 American Society of Hematology Annual Meeting & Exposition
Apr 11, 2017: Apogenix Announces Initiation of Clinical Development for ABBV-621 to Treat Solid and Hematologic Tumors by Partner AbbVie
Dec 24, 2013: KAHR Medical to Receive NIS 4 million (over $1.1 million USD) in Additional Government Grants
Feb 04, 2013: Kahr Medical Secures US Patent For Its Lead Product Candidate KAHR-101
Jun 09, 2010: Human Genome Sciences Announces Results Of Phase II Trial Of Mapatumumab In Multiple Myeloma
Mar 17, 2010: Human Genome Sciences Announces Results of Randomized Phase II Trial of Mapatumumab in Non-Small Cell Lung Cancer
Dec 20, 2008: Human Genome Sciences Initiates Second Randomized Phase II Trial Of HGS-ETR1 In Combination With Chemotherapy
Sep 02, 2008: Human Genome Sciences Reports Initial Results Of Randomized Phase II Trial Of HGS-ETR1 In Combination With Bortezomib In Advanced Multiple Myeloma
Aug 22, 2008: Human Genome Sciences Completes Enrollment In Randomized Phase II Trial Of HGS-ETR1 In Non-Small Cell Lung Cancer
Oct 24, 2007: Human Genome Sciences Presents New Data Showing Anti-Tumor Activity And Safety Of Trial Receptor Antibodies In Combination With Chemotherapy
Jul 20, 2006: Human Genome Sciences Initiates Randomized Phase II Clinical Trial Of HGS-ETR1 In Combination With Bortezomib
Dec 13, 2005: Human Genome Sciences Reports Results Of Phase 2 Clinical Trial Of HGS-ETR1 In Patients With Advanced Non-Hodgkin's Lymphoma
Nov 01, 2005: Human Genome Sciences Reports Results Of Phase 2 Clinical Trial Of HGS-ETR1 In Patients With Advanced Colorectal Cancer
Aug 18, 2005: Glaxosmithkline Exercises Option To Human Genome Sciences' Trial Receptor Antibody
Jul 05, 2005: Human Genome Sciences Reports Results Of Phase II Clinical Trial Of HGS-ETR1 In Patients With Non-Small Cell Lung Cancer
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Global Markets Direct Report Coverage
Tumor Necrosis Factor Receptor Superfamily Member 10A (Death Receptor 4 or TNF Related Apoptosis Inducing Ligand Receptor 1 or TRAIL Receptor 1 or DR4 or CD261 or TNFRSF10A) - Overview
Tumor Necrosis Factor Receptor Superfamily Member 10A (Death Receptor 4 or TNF Related Apoptosis Inducing Ligand Receptor 1 or TRAIL Receptor 1 or DR4 or CD261 or TNFRSF10A) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Tumor Necrosis Factor Receptor Superfamily Member 10A (Death Receptor 4 or TNF Related Apoptosis Inducing Ligand Receptor 1 or TRAIL Receptor 1 or DR4 or CD261 or TNFRSF10A) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Tumor Necrosis Factor Receptor Superfamily Member 10A (Death Receptor 4 or TNF Related Apoptosis Inducing Ligand Receptor 1 or TRAIL Receptor 1 or DR4 or CD261 or TNFRSF10A) - Companies Involved in Therapeutics Development
AbbVie Inc
Galaxy Biotech LLC
GlaxoSmithKline Plc
KAHR medical Ltd
Merrimack Pharmaceuticals Inc
Tumor Necrosis Factor Receptor Superfamily Member 10A (Death Receptor 4 or TNF Related Apoptosis Inducing Ligand Receptor 1 or TRAIL Receptor 1 or DR4 or CD261 or TNFRSF10A) - Drug Profiles
ABBV-621 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AY-4 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Biologic to Agonize TRAIL Receptor 1 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CD19L-sTRAIL - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
dulanermin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Fusion Protein to Agonize DR4 and DR5 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HuD-114 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HuYON-007 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KAHR-101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
M-921 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
mapatumumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Recombinant Protein for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Recombinant Protein to Agonize TNFRSF10A, TNFRSF10B, TNFRSF10C and TNFRSF10D for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SCB-313 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SL-231 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Agonize DR4 and DR5 for Colorectal Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Tumor Necrosis Factor Receptor Superfamily Member 10A (Death Receptor 4 or TNF Related Apoptosis Inducing Ligand Receptor 1 or TRAIL Receptor 1 or DR4 or CD261 or TNFRSF10A) - Dormant Products
Tumor Necrosis Factor Receptor Superfamily Member 10A (Death Receptor 4 or TNF Related Apoptosis Inducing Ligand Receptor 1 or TRAIL Receptor 1 or DR4 or CD261 or TNFRSF10A) - Discontinued Products
Tumor Necrosis Factor Receptor Superfamily Member 10A (Death Receptor 4 or TNF Related Apoptosis Inducing Ligand Receptor 1 or TRAIL Receptor 1 or DR4 or CD261 or TNFRSF10A) - Product Development Milestones
Featured News & Press Releases
Nov 21, 2017: AbbVie to Present Data on Cancer Drug Candidate ABBV-621 at the 2017 American Society of Hematology Annual Meeting & Exposition
Apr 11, 2017: Apogenix Announces Initiation of Clinical Development for ABBV-621 to Treat Solid and Hematologic Tumors by Partner AbbVie
Dec 24, 2013: KAHR Medical to Receive NIS 4 million (over $1.1 million USD) in Additional Government Grants
Feb 04, 2013: Kahr Medical Secures US Patent For Its Lead Product Candidate KAHR-101
Jun 09, 2010: Human Genome Sciences Announces Results Of Phase II Trial Of Mapatumumab In Multiple Myeloma
Mar 17, 2010: Human Genome Sciences Announces Results of Randomized Phase II Trial of Mapatumumab in Non-Small Cell Lung Cancer
Dec 20, 2008: Human Genome Sciences Initiates Second Randomized Phase II Trial Of HGS-ETR1 In Combination With Chemotherapy
Sep 02, 2008: Human Genome Sciences Reports Initial Results Of Randomized Phase II Trial Of HGS-ETR1 In Combination With Bortezomib In Advanced Multiple Myeloma
Aug 22, 2008: Human Genome Sciences Completes Enrollment In Randomized Phase II Trial Of HGS-ETR1 In Non-Small Cell Lung Cancer
Oct 24, 2007: Human Genome Sciences Presents New Data Showing Anti-Tumor Activity And Safety Of Trial Receptor Antibodies In Combination With Chemotherapy
Jul 20, 2006: Human Genome Sciences Initiates Randomized Phase II Clinical Trial Of HGS-ETR1 In Combination With Bortezomib
Dec 13, 2005: Human Genome Sciences Reports Results Of Phase 2 Clinical Trial Of HGS-ETR1 In Patients With Advanced Non-Hodgkin's Lymphoma
Nov 01, 2005: Human Genome Sciences Reports Results Of Phase 2 Clinical Trial Of HGS-ETR1 In Patients With Advanced Colorectal Cancer
Aug 18, 2005: Glaxosmithkline Exercises Option To Human Genome Sciences' Trial Receptor Antibody
Jul 05, 2005: Human Genome Sciences Reports Results Of Phase II Clinical Trial Of HGS-ETR1 In Patients With Non-Small Cell Lung Cancer
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products under Development by Stage of Development, H2 2017
Number of Products under Development by Therapy Areas, H2 2017
Number of Products under Development by Indication, H2 2017
Number of Products under Development by Companies, H2 2017
Products under Development by Companies, H2 2017
Products under Development by Companies, H2 2017 (Contd.1), H2 2017
Number of Products under Investigation by Universities/Institutes, H2 2017
Products under Investigation by Universities/Institutes, H2 2017
Number of Products by Stage and Mechanism of Actions, H2 2017
Number of Products by Stage and Route of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017
Pipeline by AbbVie Inc, H2 2017
Pipeline by Galaxy Biotech LLC, H2 2017
Pipeline by GlaxoSmithKline Plc, H2 2017
Pipeline by KAHR medical Ltd, H2 2017
Pipeline by Merrimack Pharmaceuticals Inc, H2 2017
Dormant Projects, H2 2017
Discontinued Products, H2 2017
Number of Products under Development by Stage of Development, H2 2017
Number of Products under Development by Therapy Areas, H2 2017
Number of Products under Development by Indication, H2 2017
Number of Products under Development by Companies, H2 2017
Products under Development by Companies, H2 2017
Products under Development by Companies, H2 2017 (Contd.1), H2 2017
Number of Products under Investigation by Universities/Institutes, H2 2017
Products under Investigation by Universities/Institutes, H2 2017
Number of Products by Stage and Mechanism of Actions, H2 2017
Number of Products by Stage and Route of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017
Pipeline by AbbVie Inc, H2 2017
Pipeline by Galaxy Biotech LLC, H2 2017
Pipeline by GlaxoSmithKline Plc, H2 2017
Pipeline by KAHR medical Ltd, H2 2017
Pipeline by Merrimack Pharmaceuticals Inc, H2 2017
Dormant Projects, H2 2017
Discontinued Products, H2 2017
LIST OF FIGURES
Number of Products under Development by Stage of Development, H2 2017
Number of Products under Development by Therapy Areas, H2 2017
Number of Products under Development by Top 10 Indications, H2 2017
Number of Products by Stage and Mechanism of Actions, H2 2017
Number of Products by Stage and Route of Administration, H2 2017
Number of Products by Molecule Types, H2 2017
Number of Products by Stage and Molecule Types, H2 2017
COMPANIES MENTIONED
AbbVie Inc
Galaxy Biotech LLC
GlaxoSmithKline Plc
KAHR medical Ltd
Merrimack Pharmaceuticals Inc
Number of Products under Development by Stage of Development, H2 2017
Number of Products under Development by Therapy Areas, H2 2017
Number of Products under Development by Top 10 Indications, H2 2017
Number of Products by Stage and Mechanism of Actions, H2 2017
Number of Products by Stage and Route of Administration, H2 2017
Number of Products by Molecule Types, H2 2017
Number of Products by Stage and Molecule Types, H2 2017
COMPANIES MENTIONED
AbbVie Inc
Galaxy Biotech LLC
GlaxoSmithKline Plc
KAHR medical Ltd
Merrimack Pharmaceuticals Inc
